Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Back

ESC Premium Access

Clinical Efficacy and Safety of Achieving Very Low LDL-C Levels With the PCSK9 Inhibitor Evolocumab in the FOURIER Outcomes Trial

Session: Clinical Trial Update 1

Topic: Lipids (Epidemiology and Prevention)

Speaker: Doctor R. Giugliano (Boston, US)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Robert Giugliano

Brigham and Women's Hospital, Boston (United States of America)

13 presentations

1 follower

5 more presentations in this session

Increased all-cause mortality with intensive blood-pressure control in patients with a baseline systolic blood pressure of >=160 mmHg and a Lower Framingham risk score: a cautionary note from SPRINT

Speaker: Professor T. Wang (Taipei, TW)

Access

Slides

Video

Systolic Blood Pressure Variability and Major Adverse Outcomes in Patients with Atrial Fibrillation: the AFFIRM Study

Speaker: Associate Professor M. Proietti (Milan, IT)

Access

Slides

Video

The long-term efficacy and safety of short dual antiplatelet therapy

Speaker: Professor M. Nakamura (Tokyo, JP)

Access

Slides

Video

Mechanisms for the benefit of spironolactone in resistant hypertension in the PATHWAY-2 study

Speaker: Professor B. Williams (London, GB)

Access

Slides

Video

Aldosterone Lethal Effects Blocked in Acute Myocardial Infarction Treated With or Without Reperfusion to Improve Outcome and Survival at Six Months Follow-up

Speaker: Professor F. Beygui (Caen, FR)

Access

Slides

Video

Access the full session

Clinical Trial Update 1

Speakers: Doctor R. Giugliano, Professor T. Wang, Associate Professor M. Proietti, Professor M. Nakamura, Professor B. Williams...

Access

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources